Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
TP53 disruption is the strongest predictor for Small-cell lymphoma / Chronic Lymphocytic Leukemia (CLL) of chemo-refractoriness and its assessment is the first decisional node in the disease treatment algorithm.
Potential therapeutic options for TP53 disrupted patients are e.g., i) agents circumventing TP53 disruption; ii) targeted therapies restoring the physiological function of mutant p53; and iii) medicines potentiating p53 function.
B-cell receptor (BCR) inhibitors and BCL2 inhibitors have significantly improved CLL survival, however TP53 disrupted patients s…